Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy
- 17 May 2013
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 30 (3) , 1-7
Abstract
Tau is a microtubule-associated protein and expressed in normal breast epithelial cells and breast cancer. Tau expression in breast cancer may be important for chemotherapy optimization. This study is to investigate the expression of Tau in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy. Levels of Tau protein in advanced breast cancer were detected immunohistochemically. The chemotherapeutic efficacy indexes in Tau− group, which includes the remission rate, Miller-Payne pathological reactive grade, and pathologic complete response rate, were improved compared with that in Tau+ group. There was difference in the efficacy indexes among ER+ subgroups but not among ER− patients. In addition, Tau expression was positively correlated (r = 0.32, P < 0.00). In multivariate analysis, when age, clinical stage, postoperative lymph node metastasis, ER, PR, HER2, Ki-67, TP53, or Tau status were included, postoperative lymph node metastasis and Tau-negative status were identified as independent predictors of pathologic complete response. In conclusion, negative Tau protein expression may be an effective predictor for taxane-containing neoadjuvant chemotherapy, especially in ER+ subgroups. Further study on the molecular mechanism and utility of Tau for individualizing adjuvant chemotherapy is warranted.Keywords
This publication has 30 references indexed in Scilit:
- Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrestOncogene, 2011
- Adjuvant Chemotherapy, with or without Taxanes, in Early or Operable Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698 PatientsPLOS ONE, 2011
- Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohortsBreast Cancer Research, 2011
- The role of Tau protein in resistance to paclitaxelCancer Chemotherapy and Pharmacology, 2011
- Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trialBreast Cancer Research and Treatment, 2008
- Taxanes, microtubules and chemoresistant breast cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2008
- HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combinationBMC Cancer, 2007
- Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor responseThe Breast, 2007
- Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging ManualCA: A Cancer Journal for Clinicians, 2006
- Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancerProceedings of the National Academy of Sciences, 2005